Arthur Copstein

Appriva Medical, Inc. designs, develops and manufactures medical devices. The firm's products include manufacturing of closed-chest, catheter-based device for occluding the left atrial appendage and PLAATO. The company was founded by Dr. Lesh and Erik van der Burg in 1998 and is headquartered in Sunnyvale, CA

UCSF Medical Center owns and operates hospitals. It operates hospitals in San Francisco as well as satellite facilities. It provides health care facilities to children, organ transplants, cardiac care, fertility treatments, neurosurgery, ophthalmology, and orthopedics. It also provides outpatient care and some programs in areas as women's health, aging, cancer, and pain management. UCSF Medical Center is headquartered in San Francisco, CA.

Middle Peak Medical, Inc. develops implants for treatment of mitral valve disease. Its technology has application in both percutaneous catheter-based intervention and in minimally invasive or open-heart cardiac surgery. The company was founded by Michael D. Lesh and Alexander Khairkhahan in 2011 and is headquartered in Palo Alto, CA.

Cordance Medical, Inc. is a company that is developing the NeuroAccess™ focused ultrasound system to treat Alzheimer's disease. The company is based in Mountain View, CA. Alzheimer's disease is a progressive disease that affects memory and makes up an estimated 60-80% of dementia cases. Cordance's solution is a non-invasive 30-minute outpatient clinic procedure that opens the blood-brain barrier precisely to physician-directed regions of the brain. The company's cornerstone patent has been granted claims in the US, AU, and ten other countries. The company was founded by Bhaskar Ramamurthy. The CEO is Ryan Dittamore.

Elucid Bioimaging is a medical technology company based in the United States that aims to understand and treat the underlying cause of heart attacks and strokes, specifically subclinical atherosclerosis. The company is based in Boston, MA and was founded in 2009 by Andrew Buckler. The company uses AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease. Elucid Bioimaging's proprietary software, Vascucap, is the first tool to quantify atherosclerotic plaque against histology, deliver key arterial measures, and provide 3D visualization to inform the risk of events such as stroke or heart attack. Vascucap's unique information informs better treatment decisions by physicians, leading to better patient outcomes at a reduced cost of care. The CEO is Blake Richards.